Cubist Systematic Strategies LLC Raises Stock Holdings in Mesoblast Limited $MESO

Key Points

• Cubist Systematic Strategies LLC increased its stake in Mesoblast Limited by 104.3% during the first quarter, owning 71,891 shares valued at approximately $897,000.
• Brokerages have mixed views on Mesoblast, with Canaccord Genuity upgrading the stock to a "strong-buy" rating, while Jefferies Financial Group downgraded it to a "hold," resulting in a consensus rating of "Buy" with a price target of $18.00.
• Mesoblast's stock performance shows a one-year range between $6.00 and $22.00, with the current price opening at $15.00 on Wednesday.

Cubist Systematic Strategies LLC lifted its holdings in Mesoblast Limited (NASDAQ:MESO - Free Report) by 104.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 71,891 shares of the company's stock after acquiring an additional 36,700 shares during the period. Cubist Systematic Strategies LLC owned 0.06% of Mesoblast worth $897,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Barclays PLC bought a new position in shares of Mesoblast in the fourth quarter worth about $38,000. BNP Paribas Financial Markets lifted its position in shares of Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after buying an additional 2,597 shares in the last quarter. Advisors Preferred LLC lifted its position in shares of Mesoblast by 224.9% in the first quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock worth $54,000 after buying an additional 3,169 shares in the last quarter. Choreo LLC purchased a new stake in Mesoblast during the first quarter valued at approximately $128,000. Finally, OLD Mission Capital LLC purchased a new stake in Mesoblast during the first quarter valued at approximately $148,000. Institutional investors own 1.43% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Canaccord Genuity Group upgraded Mesoblast to a "strong-buy" rating in a research report on Tuesday, August 5th. Jefferies Financial Group cut Mesoblast from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Mesoblast has a consensus rating of "Buy" and a consensus target price of $18.00.

Mesoblast Stock Up 3.1%

MESO stock traded up $0.47 during midday trading on Monday, reaching $15.29. The stock had a trading volume of 37,680 shares, compared to its average volume of 272,959. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.77 and a current ratio of 1.99. The firm has a fifty day simple moving average of $14.47 and a two-hundred day simple moving average of $12.73. Mesoblast Limited has a 52-week low of $6.00 and a 52-week high of $22.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.